Immunotherapy of melanoma: Present options and future promises

Cancer and Metastasis Reviews

Volumn 34, Issue 1, 2015, Pages 115-128

  Rotte, Anand ^a,b   Bhandaru, Madhuri ^a,b   Zhou, Youwen ^a,b,c   McElwee, Kevin J ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Clinical trials; Immunotherapy; Ipilimumab; Melanoma; Vaccines

Indexed keywords

CANCER VACCINE; INTERLEUKIN 2; IPILIMUMAB; MONOCLONAL ANTIBODY;

ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); FORECASTING; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; METASTASIS; PATHOLOGY; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION; TRENDS;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; FORECASTING; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MELANOMA; NEOPLASM METASTASIS; T-LYMPHOCYTES;

EID: 84925453223     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-014-9542-0     Document Type: Article

References (84)

1. Miller, A. J., & Mihm, M. C., Jr. (2006). Melanoma. New England Journal of Medicine, 355(1), 51–65. doi:10.1056/NEJMra052166.
2. Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 63(1), 11–30. doi:10.3322/caac.21166.
3. Cheng, Y., Zhang, G., & Li, G. (2013). Targeting MAPK pathway in melanoma therapy. Cancer and Metastasis Reviews, 32(3–4), 567–584. doi:10.1007/s10555-013-9433-9.
4. Saranga-Perry, V., Ambe, C., Zager, J. S., & Kudchadkar, R. R. (2014). Recent developments in the medical and surgical treatment of melanoma. CA: A Cancer Journal for Clinicians, 64(3), 171–185. doi:10.3322/caac.21224.
5. Finn, L., Markovic, S. N., & Joseph, R. W. (2012). Therapy for metastatic melanoma: the past, present, and future. BMC Medicine, 10, 23. doi:10.1186/1741-7015-10-23.
6. Hodi, F. S., Oble, D. A., Drappatz, J., Velazquez, E. F., Ramaiya, N., Ramakrishna, N., et al. (2008). CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nature Clinical Practice Oncology, 5(9), 557–561. doi:10.1038/ncponc1183.
7. Hodi, F. S., O’Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711–723. doi:10.1056/NEJMoa1003466.
8. Robert, C., Thomas, L., Bondarenko, I., O’Day, S., Weber, J., Garbe, C., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364(26), 2517–2526. doi:10.1056/NEJMoa1104621.
9. Postow, M. A., Luke, J. J., Bluth, M. J., Ramaiya, N., Panageas, K. S., Lawrence, D. P., et al. (2013). Ipilimumab for patients with advanced mucosal melanoma. The Oncologist, 18(6), 726–732. doi:10.1634/theoncologist. 2012-0464.
10. Rosenberg, S. A. (2014). IL-2: the first effective immunotherapy for human cancer. Journal of Immunology, 192(12), 5451–5458. doi:10.4049/jimmunol.1490019.
11. Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., et al. (1999). High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology, 17(7), 2105–2116.
12. Kaufman, H. L., Kirkwood, J. M., Hodi, F. S., Agarwala, S., Amatruda, T., Bines, S. D., et al. (2013). The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Reviews. Clinical Oncology, 10(10), 588–598. doi:10.1038/nrclinonc.2013.153.
13. Okuyama, S., Gonzalez, R., & Lewis, K. D. (2010). Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review. Core Evidence, 5, 39–48.
14. Kirkwood, J. M., & Ernstoff, M. S. (1984). Interferons in the treatment of human cancer. Journal of Clinical Oncology, 2(4), 336–352.
15. Tarhini, A. A., Gogas, H., & Kirkwood, J. M. (2012). IFN-alpha in the treatment of melanoma. Journal of Immunology, 189(8), 3789–3793. doi:10.4049/jimmunol.1290060.
16. Herndon, T. M., Demko, S. G., Jiang, X., He, K., Gootenberg, J. E., Cohen, M. H., et al. (2012). U.S. food and drug administration approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma. The Oncologist, 17(10), 1323–1328. doi:10.1634/theoncologist. 2012-0123.
17. Weber, J. (2007). Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. The Oncologist, 12(7), 864–872. doi:10.1634/theoncologist.12-7-864.
18. Dariavach, P., Mattei, M. G., Golstein, P., & Lefranc, M. P. (1988). Human Ig superfamily CTLA-4 gene: Chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. European Journal of Immunology, 18(12), 1901–1905. doi:10.1002/eji.1830181206.
19. Karandikar, N. J., Vanderlugt, C. L., Walunas, T. L., Miller, S. D., & Bluestone, J. A. (1996). CTLA-4: a negative regulator of autoimmune disease. Journal of Experimental Medicine, 184(2), 783–788.
20. Walunas, T. L., Bakker, C. Y., & Bluestone, J. A. (1996). CTLA-4 ligation blocks CD28-dependent T cell activation. Journal of Experimental Medicine, 183(6), 2541–2550.
21. Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., et al. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America, 100(14), 8372–8377. doi:10.1073/pnas.1533209100.
22. Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. New England Journal of Medicine, 369(2), 122–133. doi:10.1056/NEJMoa1302369.
23. Kyi, C., & Postow, M. A. (2014). Checkpoint blocking antibodies in cancer immunotherapy. FEBS Letters, 588(2), 368–376. doi:10.1016/j.febslet.2013.10.015.
24. McDermott, D. F., & Atkins, M. B. (2013). PD-1 as a potential target in cancer therapy. Cancer Medicine, 2(5), 662–673. doi:10.1002/cam4.106.
25. Merelli, B., Massi, D., Cattaneo, L., & Mandala, M. (2014). Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Critical Reviews in Oncology/Hematology, 89(1), 140–165. doi:10.1016/j.critrevonc.2013.08.002.
26. Zou, W., & Chen, L. (2008). Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews Immunology, 8(6), 467–477. doi:10.1038/nri2326.
27. Inman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I., et al. (2007). PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: Associations with localized stage progression. Cancer, 109(8), 1499–1505. doi:10.1002/cncr.22588.
28. Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., et al. (2004). Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 101(49), 17174–17179. doi:10.1073/pnas.0406351101.
29. Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., et al. (2007). Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clinical Cancer Research, 13(7), 2151–2157. doi:10.1158/1078-0432.CCR-06-2746.
30. Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., et al. (2007). Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 104(9), 3360–3365. doi:10.1073/pnas.0611533104.
31. Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., et al. (2003). Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Research, 63(21), 7462–7467.
32. Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., et al. (2014). Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Journal of Clinical Oncology, 32(10), 1020–1030. doi:10.1200/JCO.2013.53.0105.
33. Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., et al. (2014). Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, 384(9948), 1109–1117. doi:10.1016/S0140-6736(14)60958-2.
34. Thomas, L. J., He, L. Z., Marsh, H., & Keler, T. (2014). Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity. Oncoimmunology, 3(1), e27255. doi:10.4161/onci.27255.
35. Denoeud, J., & Moser, M. (2011). Role of CD27/CD70 pathway of activation in immunity and tolerance. Journal of Leukocyte Biology, 89(2), 195–203. doi:10.1189/jlb.0610351.
36. Schaer, D. A., Hirschhorn-Cymerman, D., & Wolchok, J. D. (2014). Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. Journal of Immunotherapy Cancer, 2, 7. doi:10.1186/2051-1426-2-7.
37. Vitale, L. A., He, L. Z., Thomas, L. J., Widger, J., Weidlick, J., Crocker, A., et al. (2012). Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clinical Cancer Research, 18(14), 3812–3821. doi:10.1158/1078-0432.CCR-11-3308.
38. Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005). The B7 family revisited. Annual Review of Immunology, 23, 515–548. doi:10.1146/annurev.immunol.23.021704.115611.
39. Leitner, J., Klauser, C., Pickl, W. F., Stockl, J., Majdic, O., Bardet, A. F., et al. (2009). B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. European Journal of Immunology, 39(7), 1754–1764. doi:10.1002/eji.200839028.
40. Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., et al. (2001). B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nature Immunology, 2(3), 269–274. doi:10.1038/85339.
41. Loo, D., Alderson, R. F., Chen, F. Z., Huang, L., Zhang, W., Gorlatov, S., et al. (2012). Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clinical Cancer Research, 18(14), 3834–3845. doi:10.1158/1078-0432.CCR-12-0715.
42. Daleke, D. L. (2003). Regulation of transbilayer plasma membrane phospholipid asymmetry. Journal of Lipid Research, 44(2), 233–242. doi:10.1194/jlr. R200019-JLR200.
43. Lang, F., Gulbins, E., Lang, P. A., Zappulla, D., & Foller, M. (2010). Ceramide in suicidal death of erythrocytes. Cellular Physiology and Biochemistry, 26(1), 21–28. doi:10.1159/000315102.
44. Lang, F., & Qadri, S. M. (2012). Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purification, 33(1–3), 125–130. doi:10.1159/000334163.
45. Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998). Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. Journal of Clinical Investigation, 101(4), 890–898. doi:10.1172/JCI1112.
46. Gerber, D. E., Stopeck, A. T., Wong, L., Rosen, L. S., Thorpe, P. E., Shan, J. S., et al. (2011). Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clinical Cancer Research, 17(21), 6888–6896. doi:10.1158/1078-0432.CCR-11-1074.
47. Kaufman, H. L., Ruby, C. E., Hughes, T., & Slingluff, C. L., Jr. (2014). Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. Journal of Immunotherapy Cancer, 2, 11. doi:10.1186/2051-1426-2-11.
48. Shi, Y., Liu, C. H., Roberts, A. I., Das, J., Xu, G., Ren, G., et al. (2006). Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don’t know. Cell Research, 16(2), 126–133. doi:10.1038/sj.cr.7310017.
49. Matzinger, P. (2002). The danger model: a renewed sense of self. Science, 296(5566), 301–305. doi:10.1126/science.1071059.
50. Traversari, C., van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., Van Pel, A., et al. (1992). A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. Journal of Experimental Medicine, 176(5), 1453–1457.
51. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., et al. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254(5038), 1643–1647.
52. Aranda, F., Vacchelli, E., Eggermont, A., Galon, J., Sautes-Fridman, C., Tartour, E., et al. (2013). Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology, 2(12), e26621. doi:10.4161/onci.26621.
53. Murakami, T., & Sunada, Y. (2011). Plasmid DNA gene therapy by electroporation: Principles and recent advances. Current Gene Therapy, 11(6), 447–456.
54. USDA licenses DNA vaccine for treatment of melanoma in dogs (2010). J Am Vet Med Assoc, 236(5), 495, doi: 10.2460/javma.236.5.488.
55. Bergman, P. J., Camps-Palau, M. A., McKnight, J. A., Leibman, N. F., Craft, D. M., Leung, C., et al. (2006). Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine, 24(21), 4582–4585. doi:10.1016/j.vaccine.2005.08.027.
56. Bergman, P. J., McKnight, J., Novosad, A., Charney, S., Farrelly, J., Craft, D., et al. (2003). Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clinical Cancer Research, 9(4), 1284–1290.
57. Palucka, K., & Banchereau, J. (2012). Cancer immunotherapy via dendritic cells. Nature Reviews Cancer, 12(4), 265–277. doi:10.1038/nrc3258.
58. El Marsafy, S., Bagot, M., Bensussan, A., & Mauviel, A. (2009). Dendritic cells in the skin—Potential use for melanoma treatment. Pigment Cell & Melanoma Research, 22(1), 30–41. doi:10.1111/j.1755-148X.2008.00532.x.
59. Radford, K. J., Tullett, K. M., & Lahoud, M. H. (2014). Dendritic cells and cancer immunotherapy. Current Opinion in Immunology, 27, 26–32. doi:10.1016/j.coi.2014.01.005.
60. Kobayashi, M., Suzuki, K., Yashi, M., Yuzawa, M., Takayashiki, N., & Morita, T. (2007). Tumor infiltrating dendritic cells predict treatment response to immunotherapy in patients with metastatic renal cell carcinoma. Anticancer Research, 27(2), 1137–1141.
61. Simonetti, O., Goteri, G., Lucarini, G., Rubini, C., Stramazzotti, D., Lo Muzio, L., et al. (2007). In melanoma changes of immature and mature dendritic cell expression correlate with tumor thickness: an immunohistochemical study. International Journal of Immunopathology and Pharmacology, 20(2), 325–333.
62. Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F., & Berneman, Z. N. (2014). Clinical use of dendritic cells for cancer therapy. Lancet Oncology, 15(7), e257–e267. doi:10.1016/S1470-2045(13)70585-0.
63. Weber, J., Atkins, M., Hwu, P., Radvanyi, L., Sznol, M., & Yee, C. (2011). White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clinical Cancer Research, 17(7), 1664–1673. doi:10.1158/1078-0432.CCR-10-2272.
64. Park, T. S., Rosenberg, S. A., & Morgan, R. A. (2011). Treating cancer with genetically engineered T cells. Trends in Biotechnology, 29(11), 550–557. doi:10.1016/j.tibtech.2011.04.009.
65. Lee, S., & Margolin, K. (2012). Tumor-infiltrating lymphocytes in melanoma. Current Oncology Reports, 14(5), 468–474. doi:10.1007/s11912-012-0257-5.
66. Urba, W. J. (2014). At the bench: Adoptive cell therapy for melanoma. Journal of Leukocyte Biology, 95(6), 867–874. doi:10.1189/jlb.0513301.
67. Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C. N., Sloss, C. M., et al. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Research, 70(13), 5213–5219. doi:10.1158/0008-5472.CAN-10-0118.
68. Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., et al. (2012). Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clinical Cancer Research, 18(5), 1386–1394. doi:10.1158/1078-0432.CCR-11-2479.
69. Koya, R. C., Mok, S., Otte, N., Blacketor, K. J., Comin-Anduix, B., Tumeh, P. C., et al. (2012). BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Research, 72(16), 3928–3937. doi:10.1158/0008-5472.CAN-11-2837.
70. Eggermont, A. M., Suciu, S., Testori, A., Santinami, M., Kruit, W. H., Marsden, J., et al. (2012). Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. Journal of Clinical Oncology, 30(31), 3810–3818. doi:10.1200/JCO.2011.41.3799.
71. Kelderman, S., Schumacher, T. N., & Haanen, J. B. (2014). Acquired and intrinsic resistance in cancer immunotherapy. Molecular Oncology. doi:10.1016/j.molonc.2014.07.011.
72. Baitsch, L., Fuertes-Marraco, S. A., Legat, A., Meyer, C., & Speiser, D. E. (2012). The three main stumbling blocks for anticancer T cells. Trends in Immunology, 33(7), 364–372. doi:10.1016/j.it.2012.02.006.
73. Besedovsky, L., Lange, T., & Born, J. (2012). Sleep and immune function. Pflügers Archiv, 463(1), 121–137. doi:10.1007/s00424-011-1044-0.
74. Segerstrom, S. C., & Miller, G. E. (2004). Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychological Bulletin, 130(4), 601–630. doi:10.1037/0033-2909.130.4.601.
75. Kasparian, N. A. (2013). Psychological care for people with melanoma: what, when, why and how? Seminars in Oncology Nursing, 29(3), 214–222. doi:10.1016/j.soncn.2013.06.007.
76. Kasparian, N. A. (2013). Psychological stress and melanoma: are we meeting our patients’ psychological needs? Clinics in Dermatology, 31(1), 41–46. doi:10.1016/j.clindermatol.2011.11.005.
77. Fellner, C. (2012). Ipilimumab (yervoy) prolongs survival in advanced melanoma: Serious side effects and a hefty price tag may limit its use. P T, 37(9), 503–530.
78. Jonsson, B., & Wilking, N. (2012). Cancer vaccines and immunotherapeutics: Challenges for pricing, reimbursement and market access. Human Vaccin Immunotherapy, 8(9), 1360–1363. doi:10.4161/hv.21921.
79. Ma, C., & Armstrong, A. W. (2014). Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. The Journal of Dermatological Treatment, 25(5), 401–408. doi:10.3109/09546634.2013.813897.
80. Amos, S. M., Duong, C. P., Westwood, J. A., Ritchie, D. S., Junghans, R. P., Darcy, P. K., et al. (2011). Autoimmunity associated with immunotherapy of cancer. Blood, 118(3), 499–509. doi:10.1182/blood-2011-01-325266.
81. Lacouture, M. E., Wolchok, J. D., Yosipovitch, G., Kahler, K. C., Busam, K. J., & Hauschild, A. (2014). Ipilimumab in patients with cancer and the management of dermatologic adverse events. Journal of the American Academy of Dermatology, 71(1), 161–169. doi:10.1016/j.jaad.2014.02.035.
82. Minkis, K., Garden, B. C., Wu, S., Pulitzer, M. P., & Lacouture, M. E. (2013). The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. Journal of the American Academy of Dermatology, 69(3), e121–e128. doi:10.1016/j.jaad.2012.12.963.
83. Bouwhuis, M. G., Ten Hagen, T. L., Suciu, S., & Eggermont, A. M. (2011). Autoimmunity and treatment outcome in melanoma. Current Opinion in Oncology, 23(2), 170–176. doi:10.1097/CCO.0b013e328341edff.
84. Hinds, A. M., Ahmad, D. S., Muenster, J. E., Berg, Z. M., Lopez, K. T., Holly, J. S., et al. (2014). Ipilimumab-induced colitis: a rare but serious side effect. Endoscopy, 46(Suppl 1 UCTN), E308–E309. doi:10.1055/s-0034-1377209.